Skip to main content
Category

Investors

Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin

 December 17, 2020
December 17, 2020

Live webcast of the Shareholders’ Meeting on Tuesday, December 15, 2020

 December 11, 2020
December 11, 2020

MedinCell publishes its first-half 2020/2021 financial results (April – September 2020): operating expenses and portfolio development in line with expectations

 December 9, 2020
December 9, 2020

MedinCell publishes its financial results and activity report for the first half of 2021-2022

 December 8, 2020
December 8, 2020

Videoconference and publication of the 2020-2021 Half-Year Results, on December 9, 2020

 December 2, 2020
December 2, 2020

First long-acting injectable (LAI) antipsychotic using MedinCell’s technology reaches Phase 3 clinical study primary completion date

 November 12, 2020
November 12, 2020

Convening of the General Assembly: Proposal for the appointment of Elisabeth Kogan to the Supervisory Board

 November 9, 2020
November 9, 2020

MedinCell initiates the first clinical trial of its Covid-19 prevention program

 September 29, 2020
September 29, 2020

MedinCell releases the results of its September 10, 2020 ordinary annual and extraordinary general meeting

 September 11, 2020
September 11, 2020